Tagged with Merck,

Long Read Accounting for less than two percent of the global pharmaceutical market, the Middle East has long been somewhat overlooked by many drug makers, most of whom seemed more intent on chasing demand in the decidedly more populous Asian market space. But, with an estimated annual growth rate of 10 percent,…

Morocco Taher Hassen, GM for Morocco and Tunisia at Merck, gives insights into navigating market access in the complex Moroccan pharma market, outlines, the challenge of introducing biosimilars, and the enduring importance of North Africa for Merck.   Morocco is a very attractive country in terms of investment, given its stable…

Romania Despite the challenging characteristics of the Romanian market, with a large population of nearly 20 million people and significant unmet medical needs, the country will undoubtedly continue to be strategic to multinationals in the region. This also means a consistent cycling of general managers, whether they are dispatched to the…

Belgium Christos Andriopoulos, managing director of Merck, speaks about his experience transitioning from global operations to leading a country subsidiary. Andriopoulos goes on to explain the company’s unique positioning as an innovative specialty pharma player balancing a core business with an increasing focus on specialty areas. He also offers insights on…

Switzerland German biopharma giant Merck is investing EUR 250 million in a new Swiss biotech development facility; underscoring the company’s reliance on Switzerland for the manufacturing of advanced biologicals.   The Merck Biotech Development Center is to be located in Corsier-sur-Vevey, south-western Switzerland, close to the firm’s existing biotech commercial manufacturing…

UAE In some respects, is it perhaps the medtech sector that has most to be excited about in the UAE’s domestic market, given the country’s unrelenting enthusiasm for connected devices, the Internet of Things (IoT) and digital solutions. According to a recent study carried out by INSEAD in conjunction with the…

Germany Some of the top recent stories from Germany, Europe’s leading pharma market according to CPhI, including big new investments from Merck and Bayer, the implications of the country’s new Digital Healthcare Act, the impact of the coronavirus outbreak on investor sentiment, and the health minister potentially poised to become Germany’s…

Romania Schalk Opperman, general manager of Merck Romania explains the key factors behind successful product launches in what is an unpredictable market. He shares his insights on Merck’s impressive growth in Romania and navigating the intricacies of the country’s pricing policy. In addition, he discloses advice for newcomers and reveals the…

UAE From Turkey to Tajikistan, Bangladesh to Bahrain, and Russia to Rwanda, multinational pharma firms are increasingly situating wide-ranging management responsibilities in the UAE. The following is an inexhaustive list of some of the widely varying geographies being managed from the UAE, as well as insights from the executives overseeing them.…

Talent Between 2015 and 2017 PharmaBoardroom met with pharma country managers in Mexico who spoke about the challenges and opportunities present in the Mexican market. Since then, these five stakeholders have moved on to new roles in their ever-expanding careers.    LATAM Expertise Pedro Galvis   Mexico is an interesting mix…

Pharma Faces Paolo Carli, head of Middle East, Africa, Turkey, Russia and CIS (MEAR) for Merck has continually taken on greater responsibilities in the Middle East, Africa, Turkey and Eastern Europe. In his most recent interview with PharmaBoardroom, Carli talks strategy, adaptability, and sales growth.    We look at structuring markets with…

Merck Since we last met with Paolo Carli in 2013, he has been given greater responsibilities within Merck and is now Head of Middle East, Africa, Turkey, Russia, and CIS countries for the healthcare business. Paolo discusses the logic behind being assigned such a vast region to manage, Merck’s strategy for…